|1.||Ballard, Clive: 14 articles (12/2015 - 11/2006)|
|2.||Lipton, Stuart A: 14 articles (08/2010 - 04/2003)|
|3.||Graham, Stephen M: 13 articles (01/2015 - 01/2004)|
|4.||Grossberg, George T: 12 articles (07/2015 - 01/2004)|
|5.||Serra, Gino: 10 articles (04/2015 - 05/2010)|
|6.||Aarsland, Dag: 9 articles (01/2016 - 07/2009)|
|7.||Burns, Alistair: 9 articles (12/2015 - 11/2006)|
|8.||Serra, Giulia: 9 articles (01/2015 - 05/2010)|
|9.||Parsons, Chris G: 9 articles (10/2013 - 09/2003)|
|10.||Danysz, Wojciech: 9 articles (10/2013 - 09/2003)|
|1.||Alzheimer Disease (Alzheimer's Disease)
12/01/2013 - "Behavioural symptoms are common in moderate to severe Alzheimer's disease (AD) and are improved by memantine with the most pronounced effect on agitation/aggression. "
03/01/2008 - "This post hoc analysis provides important evidence from placebo-controlled trials that memantine may be a safe and effective treatment in Alzheimer's disease patients with agitation/aggression or psychosis, who are otherwise prone to rapid progression. "
02/01/2010 - "In well designed trials in patients with moderate to severe Alzheimer's disease, oral memantine monotherapy improved outcomes in the area of functional ability more than placebo in one trial, but in a second trial, treatment differences did not reach significance. "
10/01/2009 - "In well designed trials in patients with moderate to severe Alzheimer's disease, oral memantine monotherapy improved outcomes in the area of functional ability more than placebo in one trial, but in a second trial, treatment differences did not reach significance. "
06/01/2006 - "Phase 3 (final) clinical trials have shown that memantine is effective in treating moderate-to-severe Alzheimer's disease while being well tolerated. "
03/01/2004 - "In randomized, controlled studies it has been shown that memantine is beneficial in the treatment of moderate to severe dementia of Alzheimer's type and it became the very first compound to be registered for this purpose both in Europe (including Poland) and in the United States. "
07/01/2011 - "Use of ChEIs and memantine on admission was significantly greater in residents with mild to moderately severe dementia (41.2%) than in those with advanced dementia (33.3%, P=.001). "
07/01/1995 - "In patients with dementia syndrome of various aetiologies, memantine produces a rapid onset, clinical improvement in various symptomatological deficits."
01/20/2010 - "We hypothesized that memantine, an anti-dementia drug, may be useful for the treatment of excessive daytime sleepiness. "
02/01/2011 - "An improved neuronal energy status may thus be involved in the neuroprotective effect under these conditions and may qualify memantine as potential future option to combat cognitive impairments and dementia in diabetes."
|3.||Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy)
08/01/2004 - "Memantine treatment also has demonstrated significant improvement of cognitive performance in patients suffering from vascular dementia. "
10/01/2003 - "Memantine is beneficial in the treatment of severe and moderate-to-severe AD and may also be of some benefit in the treatment of mild-to-moderate vascular dementia. "
07/01/2002 - "In patients with mild to moderate vascular dementia, memantine 20 mg/d improved cognition consistently across different cognitive scales, with at least no deterioration in global functioning and behavior. "
11/01/2002 - "The aim of the reported trial was to investigate the safety and efficacy of memantine in mild to moderate vascular dementia (VaD). "
08/01/2003 - "The efficacy of memantine in vascular dementia also requires further investigation."
05/01/2001 - "Preliminary results in a rat model for experimental glaucoma also show that, when compared to control animals, systemic treatment with memantine (10 mg/kg/day) was associated with a significant reduction in glaucoma-induced loss of retinal ganglion cells."
08/01/2004 - "Histologic measurements of RGC survival as well as tomographic measurements of nerve head topography show that systemic treatment with memantine, a compound which does not lower intraocular pressure, is both safe and effective to reduce changes associated with experimental glaucoma."
08/01/2004 - "To determine, using anatomic measurements, whether daily oral dosing with memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates. "
08/01/2004 - "Systemic treatment with memantine, a compound which does not lower intraocular pressure, was both safe and effective for reduction of functional loss associated with experimental glaucoma."
08/01/2004 - "To determine, using electrophysiological measures of visual system function, whether oral daily dosing of memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates. "
01/01/2014 - "The aim of this study was to evaluate the efficacy of a high dose memantine on neurological function of patients with ischemic stroke. "
02/01/2015 - "Low dose (0.2 mg/kg/day) memantine treatment significantly reduced lesion volume (by 30% to 50%) and improved behavioral outcomes in stroke lesions that had been separated into either small/striatal or large/striatocortical infarcts. "
06/30/1999 - "Thus memantine appears to be both safe and effective in neonatal as well as adult animal models of stroke."
01/01/2014 - "Study of the neuroprotective effects of memantine in patients with mild to moderate ischemic stroke."
02/01/2015 - "These results show that clinically established low doses of memantine should be considered for patients 'at risk' of stroke, while higher doses are contraindicated."
|3.||Cholinesterase Inhibitors (Anticholinesterases)
|6.||Glutamic Acid (Glutamate)
|1.||Activities of Daily Living (ADL)
|2.||Drug Therapy (Chemotherapy)